Please enter the email address you used to register, then we will send you a link to choose a new password
Benchmark analyst Bruce Jackson reiterates Biolase (NASDAQ:BIOL) with a Speculative Buy and maintains $0.4 price target.
Biolase (NASDAQ:BIOL) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.17) by ...
Ascendiant Capital analyst Edward Woo maintains Biolase (NASDAQ:BIOL) with a Buy and lowers the price target from $15 to $4.
Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected four...
Benchmark analyst Bruce Jackson maintains Biolase (NASDAQ:BIOL) with a Speculative Buy and lowers the price target from $2.5...
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 200 points. The Dow traded down 0....
BIOLASE, Inc. shares rise 31% after better-than-expected FY23 EPS results, strong revenue growth expected in 2024 due to increa...
U.S. stocks traded slightly lower this morning. Following the market opening Friday, the Dow traded down 0.06% to 39,758.88 whi...